Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.

Humans Multiple Myeloma / therapy Male Female Middle Aged Immunotherapy, Adoptive Aged Blood Platelets Adult Treatment Outcome Receptors, Chimeric Antigen Cytokine Release Syndrome / therapy Platelet Function Tests

Chimeric antigen receptor T cell Multiple myeloma Platelet function Prognosis Relapsed/refractory

Journal

Clinical and experimental medicine

ISSN: 1591-9528

Titre abrégé: Clin Exp Med

Pays: Italy

ID NLM: 100973405

Informations de publication

Date de publication:
04 Sep 2024

Historique:

received: 07 07 2024

accepted: 21 08 2024

medline: 4 9 2024

pubmed: 4 9 2024

entrez: 4 9 2024

Statut: epublish

Résumé

The influence of chimeric antigen receptor T (CAR-T) cell therapy on platelet function in relapsed/refractory (R/R) multiple myeloma (MM) has not been thoroughly investigated. Our cohort comprised fifty MM patients treated with CAR-T cells. The mean platelet closure time (PCT) induced by collagen/adenosine diphosphate (CADP) in peripheral blood was significantly prolonged before lymphodepletion (195.24 ± 11.740 s) and notably reduced post-CAR-T cell therapy (128.02 ± 5.60 s), with a statistically significant improvement (67.22, 95% CI 46.91-87.53, P < 0.001). This post-treatment PCT was not significantly different from that of healthy controls (10.64, 95% CI 1.11-22.40, P > 0.05). Furthermore, a pronounced enhancement in PCT was observed in patients with a response greater than partial remission (PR) following CAR-T cell infusion compared to pre-treatment values (P < 0.001). An extended PCT was also associated with a less favorable remission status. In patients with cytokine release syndrome (CRS) grades 0-2, those with a PCT over 240.5 s exhibited a shorter progression-free survival (PFS), with median PFS times of 10.2 months for the PCT > 240.5 s group versus 22.0 months for the PCT ≤ 240.5 s group. Multivariate analysis revealed that a PCT value exceeding 240.5 s is an independent prognostic factor for overall survival (OS) in R/R MM patients after CAR-T cell therapy. The study demonstrates that CAR-T cell therapy enhances platelet function in R/R MM patients, and PCT emerges as a potential prognostic biomarker for the efficacy of CAR-T cell therapy.

Identifiants

DOI: 10.1007/s10238-024-01477-y PMID: 39230837

pubmed: 39230837

doi: 10.1007/s10238-024-01477-y

pii: 10.1007/s10238-024-01477-y

doi:

Substances chimiques

Receptors, Chimeric Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

210

Subventions

Organisme : Suqian Key Laboratory of Hematology

ID : M202111

Organisme : Natural Science Foundation of Jiangsu Province

ID : BK20221218

Organisme : Development Fund of Affiliated Hospital of Xuzhou Medical University

ID : XYFY2021001

Informations de copyright

Références

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-Cell therapy in patients with relapsed or refractory multiple myeloma (cartitude-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://doi.org/10.1016/S0140-6736(21)00933-8 .

doi: 10.1016/S0140-6736(21)00933-8 pubmed: 34175021

Raje N, Berdeja J, Lin Y, et al. Anti-Bcma car T-cell therapy Bb2121 in relapsed or refractory multiple myeloma. New Engl J Med. 2019;380:12. https://doi.org/10.1056/NEJMoa1817226 .

doi: 10.1056/NEJMoa1817226

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850 .

doi: 10.1056/NEJMoa2024850 pubmed: 33626253

Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41:2583–93. https://doi.org/10.1200/jco.22.01824 .

doi: 10.1200/jco.22.01824 pubmed: 36881785 pmcid: 10414745

Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and Cd19 chimeric antigen receptor T Cells in multiple myeloma. J Clin Oncol. 2022;40:2246–56. https://doi.org/10.1200/JCO.21.01676 .

doi: 10.1200/JCO.21.01676 pubmed: 35333600

Miller A, Daum R, Wang T, et al. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024. https://doi.org/10.1016/j.jcyt.2024.04.075 .

doi: 10.1016/j.jcyt.2024.04.075 pubmed: 39078352

Mohan M, Szabo A, Patwari A, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following Bcma directed chimeric antigen receptor T (Car T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59:647–52. https://doi.org/10.1038/s41409-024-02233-2 .

doi: 10.1038/s41409-024-02233-2 pubmed: 38361116

Kuang C, Xia M, An G, et al. Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in multiple myeloma. Nat Commun. 2023;14:2093. https://doi.org/10.1038/s41467-023-37699-z .

doi: 10.1038/s41467-023-37699-z pubmed: 37055385 pmcid: 10102122

Li Z, Que Y, Wang D, et al. Recovery-model: a model for car T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma. Thromb Res. 2023;227:62–70. https://doi.org/10.1016/j.thromres.2023.05.016 .

doi: 10.1016/j.thromres.2023.05.016 pubmed: 37235950

Nagle SJ, Murphree C, Raess PW, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021;96:455–61. https://doi.org/10.1002/ajh.26113 .

doi: 10.1002/ajh.26113 pubmed: 33529419

Cieslar P, Másová L, Scheiner T, et al. Oxidative stress and platelet function in multiple myeloma and renal insufficiency: clinical relations of different tests. Thromb Res. 2002;105:277–83. https://doi.org/10.1016/s0049-3848(02)00003-8 .

doi: 10.1016/s0049-3848(02)00003-8 pubmed: 12031820

Mitchell JL, Khan D, Rana RH, et al. Multiple myeloma and its treatment contribute to increased platelet reactivity. Platelets. 2023;34:2264940. https://doi.org/10.1080/09537104.2023.2264940 .

doi: 10.1080/09537104.2023.2264940 pubmed: 37822056

Robak M, Treliński J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol. 2012;29:3574–80. https://doi.org/10.1007/s12032-012-0290-0 .

doi: 10.1007/s12032-012-0290-0 pubmed: 22772968 pmcid: 3505549

Moscardó A, Latorre A, Santos MT, Bonanad S, Vallés J. Platelet function in malignant hematological disorders. Curr Opin Oncol. 2015;27:522–31. https://doi.org/10.1097/cco.0000000000000237 .

doi: 10.1097/cco.0000000000000237 pubmed: 26447878

Favaloro EJ, Bonar R. An update on quality control for the Pfa-100/Pfa-200. Platelets. 2018;29:622–7. https://doi.org/10.1080/09537104.2018.1475636 .

doi: 10.1080/09537104.2018.1475636 pubmed: 29792545

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. https://doi.org/10.1016/s1470-2045(14)70442-5 .

doi: 10.1016/s1470-2045(14)70442-5 pubmed: 25439696

Callander NS, Baljevic M, Adekola K, et al. Nccn guidelines

doi: 10.6004/jnccn.2022.0002 pubmed: 34991075

Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. https://doi.org/10.1182/blood-2014-05-552729 .

doi: 10.1182/blood-2014-05-552729 pubmed: 24876563 pmcid: 4093680

Lee DW, Santomasso BD, Locke FL, et al. Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758 .

doi: 10.1016/j.bbmt.2018.12.758 pubmed: 30592986

Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392–7. https://doi.org/10.1161/01.Cir.0000141575.92958.9c .

doi: 10.1161/01.Cir.0000141575.92958.9c pubmed: 15313953

Djunic I, Elezovic I, Ilic V, et al. The effect of paraprotein on platelet aggregation. J Clin Lab Anal. 2014;28:141–6. https://doi.org/10.1002/jcla.21658 .

doi: 10.1002/jcla.21658 pubmed: 24395751 pmcid: 6807480

Gkalea V, Fotiou D, Dimopoulos MA, Kastritis E. Monoclonal gammopathy of thrombotic significance. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15020480 .

doi: 10.3390/cancers15020480 pubmed: 36672429

Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost: JTH. 2023;21:3005–15. https://doi.org/10.1016/j.jtha.2023.08.014 .

doi: 10.1016/j.jtha.2023.08.014 pubmed: 37625698

Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020;26:865–75. https://doi.org/10.1016/j.bbmt.2019.11.027 .

doi: 10.1016/j.bbmt.2019.11.027 pubmed: 31786240

Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int. 2016;2016:9060143. https://doi.org/10.1155/2016/9060143 .

doi: 10.1155/2016/9060143 pubmed: 27403440 pmcid: 4925965

Ware JA, Clark BA, Smith M, Salzman EW. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood. 1989;73:172–6.

doi: 10.1182/blood.V73.1.172.172 pubmed: 2910357

Pennisi M, Sanchez-Escamilla M, Flynn JR, et al. Modified easix predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5:3397–406. https://doi.org/10.1182/bloodadvances.2020003885 .

doi: 10.1182/bloodadvances.2020003885 pubmed: 34432870 pmcid: 8525234

Ke M, Kang L, Wang L, et al. Car-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. J Hematol Oncol. 2021;14:90. https://doi.org/10.1186/s13045-021-01101-6 .

doi: 10.1186/s13045-021-01101-6 pubmed: 34108020 pmcid: 8191024

Brudno JN, Kochenderfer JN. Recent advances in car T-cell toxicity: mechanisms. Manif Manag Blood Rev. 2019;34:45–55. https://doi.org/10.1016/j.blre.2018.11.002 .

doi: 10.1016/j.blre.2018.11.002